☆ 4.3 Letter

Central nervous system immune reconstitution inflammatory syndrome after ibrutinib therapy for Richter transformation

LEUKEMIA & LYMPHOMA (2017)

Journal

LEUKEMIA & LYMPHOMA

Volume 58, Issue 1, Pages 207-210

Publisher

TAYLOR & FRANCIS LTD

DOI: 10.1080/10428194.2016.1179298

Keywords

-

Categories

Oncology Hematology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Immunology

Case Report: Central Nervous System Immune Reconstitution Inflammatory Syndrome Related to Bacterial Meningitis

Mengyan Hu, Sanxin Liu, Danli Lu, Yi Zhong, Dafan Yu, Wei Qiu, Zhengqi Lu, Bingjun Zhang

Summary: CNS-IRIS is an inflammatory syndrome that may occur in previously immunocompromised patients during the restoration of immunity function. This case report presents the first instance of CNS-IRIS associated with bacterial meningitis, where the patient gradually recovered with corticosteroid therapy.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Long-Term Efficacy and Safety of Ibrutinib in the Treatment of CLL Patients: A Real Life Experience

Alessandro Broccoli, Lisa Argnani, Alice Morigi, Laura Nanni, Beatrice Casadei, Cinzia Pellegrini, Vittorio Stefoni, Pier Luigi Zinzani

Summary: Ibrutinib has shown significant clinical impact in treating patients with chronic lymphocytic leukemia, including those with unfavorable cytogenetics and molecular markers. The drug is effective and well tolerated, with durable responses and a favorable safety profile in real-life settings. Adverse reactions mainly include hematological and extrahematological toxicities.

JOURNAL OF CLINICAL MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Incidence, risk factors and treatment of central nervous system immune reconstitution inflammatory syndrome in non-HIV patients with tuberculous meningitis: a multicentre observational study

Marie Robert, Arthur Mageau, Augustin Gaudemer, Michael Thy, Nathan Peiffer Smadja, Victoire de Lastours, Thomas De Broucker, Thomas Papo, Tiphaine Goulenok, Karim Sacre

Summary: This study reports on risk factors for central nervous system immune reconstitution inflammatory syndrome (CNS-IRIS) following tuberculous meningitis (TBM) in HIV-negative patients. The results show that meningeal enhancement on brain MRI and high blood albumin level are associated with the occurrence of CNS-IRIS.

INTERNAL MEDICINE JOURNAL (2023)

Add to Collection

Review Oncology

Immune Reconstitution Inflammatory Syndrome Associated Kaposi Sarcoma

Isabelle Poizot-Martin, Sylvie Bregigeon, Romain Palich, Anne-Genevieve Marcelin, Marc-Antoine Valantin, Caroline Solas, Marianne Veyri, Jean-Philippe Spano, Alain Makinson

Summary: Kaposi sarcoma-immune reconstitution inflammatory syndrome (KS-IRIS) is a common disease among people living with HIV, despite the improvement of KS with antiretroviral therapy (ART), the occurrence of KS-IRIS still exists and is associated with significant morbidity and mortality.

CANCERS (2022)

Add to Collection

Review Oncology

Richter Syndrome

Adalgisa Condoluci, Davide Rossi

Summary: RS is an aggressive evolution of CLL/SLL, and there is a need to expand treatment options as current regimens have had limited impact on patient outcomes. Preclinical models for new drug combinations may provide insights for improving therapeutic strategies.

CURRENT ONCOLOGY REPORTS (2021)

Add to Collection

Article Immunology

An Inflammatory Composite Score Predicts Mycobacterial Immune Reconstitution Inflammatory Syndrome in People with Advanced HIV: A Prospective International Cohort Study

Caian L. Vinhaes, Virginia Sheikh, Deivide Oliveira-de-Souza, Jing Wang, Adam Rupert, Gregg Roby, Maria B. Arriaga, Kiyoshi F. Fukutani, Fred Sawe, Doug Shaffer, Jintanat Ananworanich, Nittaya Phanuphak, Bruno B. Andrade, Irini Sereti

Summary: The study found that systemic inflammatory profiles in people with severe immunosuppression can predict the development of immune reconstitution inflammatory syndrome (IRIS). By developing a composite score incorporating various biomarkers, including interleukin-6, IL-10, IL-27, sCD14, interferon-gamma, tumor necrosis factor-alpha, hyaluronic acid, D-dimer, body mass index, and hemoglobin, accurate predictions of IRIS occurrence and death risk can be made.

JOURNAL OF INFECTIOUS DISEASES (2021)

Add to Collection

Article Immunology

Lenalidomide Improves Cognitive Function and Reduces Immune Reconstitution Inflammatory Syndrome in HIV-1-Related Cryptococcal Meningitis

Ran Tao, Xiaorong Peng, Xiang Liu, Junwei Su, Guanjing Lang, Ying Huang, Yafei Zhang, Biao Zhu

Summary: Cryptococcal meningitis (CM) is a common opportunistic infection in HIV patients. This study reports two cases of CM-associated immune reconstitution inflammatory syndrome (IRIS) treated with lenalidomide, which resulted in rapid clinical remission and improved cognitive function. The study also suggests that lenalidomide may improve cognitive function by regulating intracranial inflammation through multiple pathways, not just by TNF-α blocking.

JOURNAL OF INFLAMMATION RESEARCH (2022)

Add to Collection

Article Immunology

Severe Mycobacterial Immune Reconstitution Inflammatory Syndrome (IRIS) in Advanced Human Immunodeficiency Virus (HIV) Has Features of Hemophagocytic Lymphohistiocytosis and Requires Prolonged Immune Suppression

Joseph M. Rocco, Elizabeth Laidlaw, Frances Galindo, Megan Anderson, Adam Rupert, Jeanette Higgins, Ornella Sortino, Ana M. Ortega-Villa, Virginia Sheikh, Gregg Roby, Safia Kuriakose, Andrea Lisco, Maura Manion, Irini Sereti

Summary: Severe mycobacterial IRIS in HIV can cause secondary HLH driven by pathologic IFN gamma production and T-cell activation, leading to worse outcomes. Increased ferritin, anemia, CXCL9, and sCD25 associate with this phenotype and may be used for risk stratification and treatment optimization.

CLINICAL INFECTIOUS DISEASES (2023)

Add to Collection

Article Immunology

Plasma Metabolomics Reveals Dysregulated Metabolic Signatures in HIV-Associated Immune Reconstitution Inflammatory Syndrome

Luxin Pei, Kiyoshi F. Fukutani, Rafael Tiburcio, Adam Rupert, Eric W. Dahlstrom, Frances Galindo, Elizabeth Laidlaw, Andrea Lisco, Maura Manion, Bruno B. Andrade, Irini Sereti

Summary: The study identified metabolic disturbances in IRIS before and during the event, linking oxidative stress, tryptophan pathway, and lipid signaling with IRIS development. Metabolic pathways of lipids and amino acids were significantly associated with inflammatory biomarkers like IL-12p70 and IL-8 during the IRIS event, suggesting the impact of cellular metabolism on immune cell activation and vice versa.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Article Immunology

Immune Reconstitution Inflammatory Syndrome Complicating Cryptococcal Meningitis in a Pediatric Heart Transplant Patient

Chelsea Miller, Reza Daugherty, Michael McCulloch, Ina Stephens, Peter R. Williamson

Summary: This case report discusses the diagnosis and management of immune reconstitution inflammatory syndrome associated with cryptococcal meningitis in a 10-year-old pediatric heart transplant recipient.

PEDIATRIC INFECTIOUS DISEASE JOURNAL (2022)

Add to Collection

Review Oncology

Biology and Treatment of Richter Transformation

Adalgisa Condoluci, Davide Rossi

Summary: Richter transformation (RT) is an aggressive lymphoma that develops on a background of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) with a poor prognosis. Recent developments in preclinical models and genetic rationale-based therapeutic strategies aim to improve patient outcomes in this setting.

FRONTIERS IN ONCOLOGY (2022)

Add to Collection

Article Immunology

Mycobacterial Immune Reconstitution Inflammatory Syndrome in HIV is Associated With Protein-Altering Variants in Hemophagocytic Lymphohistiocytosis-Related Genes

Joseph M. Rocco, Elizabeth Laidlaw, Frances Galindo, Megan Anderson, Ornella Sortino, Safia Kuriakose, Andrea Lisco, Maura Manion, Irini Sereti

Summary: People with HIV and mycobacterial infections may develop immune reconstitution inflammatory syndrome (IRIS) after starting antiretroviral therapy. The pathophysiology of mycobacterial-IRIS overlaps with primary hemophagocytic lymphohistiocytosis (pHLH). By evaluating protein-altering variants in genes associated with HLH, it was found that 23.2% of IRIS patients had these variants, compared to only 3.8% of those without IRIS. These findings suggest a possible genetic component in the risk of mycobacterial IRIS in people with HIV and mycobacterial infections.

JOURNAL OF INFECTIOUS DISEASES (2023)

Add to Collection

Article Pathology

Morphologic and molecular analysis of Richter syndrome in chronic lymphocytic leukaemia patients treated with ibrutinib or venetoclax

Ambrus Gango, Richard Kiss, Peter Farkas, Eid Hanna, Judit Demeter, Beata Deak, Dora Levai, Lili Kotmayer, Donat Alpar, Andras Matolcsy, Csaba Bodor, Zoltan Matrai, Botond Timar

Summary: Richter syndrome (RS) is a challenging complication with poor prognosis in CLL or SLL patients, characterized by development of high-grade lymphoma. Rare phenotypes of RS can occur during treatment with targeted therapies, and genetic factors play a key role in the pathogenesis of RS.

PATHOLOGY (2022)

Add to Collection

Review Oncology

Immunological Aspects of Richter Syndrome: From Immune Dysfunction to Immunotherapy

Abdurraouf Mokhtar Mahmoud, Gianluca Gaidano, Samir Mouhssine

Summary: Richter Syndrome is the development of aggressive lymphoma in patients with chronic lymphocytic leukemia. It occurs in 1-10% of CLL patients and is refractory to conventional therapies. Recent research has shown that this syndrome is partly related to immune system dysfunction, suggesting that immunotherapy may be an effective treatment.

CANCERS (2023)

Add to Collection

Review Immunology

Current knowledge of the immune reconstitution inflammatory syndrome in Whipple disease: a review

Xiangyi Song, Ruifeng Duan, Liwei Duan, Lijuan Wei

Summary: Immune reconstitution inflammatory syndrome (IRIS) is an exaggerated and dysregulated inflammatory response that occurs as a result of immune reconstitution. It is associated with various microorganisms, and Whipple disease (WD) is one of the infectious disorders that can lead to IRIS. Recent studies on the intestinal mucosal immune system have provided new insights into the pathogenesis of IRIS, which can be used to develop monitoring tools for disease prevention and treatment strategies.

FRONTIERS IN IMMUNOLOGY (2023)

Add to Collection

Article Oncology

Pharmacologic Reduction of Mitochondrial Iron Triggers a Noncanonical BAX/BAK Dependent Cell Death

Sylvain Garciaz, Andrew A. Guirguis, Sebastian Muller, Fiona C. Brown, Yih-Chih Chan, Ali Motazediani, Caitlin L. Rowe, James A. Kuzich, Kah Lok Chan, Kevin Tran, Lorey Smith, Laura MacPherson, Brian Liddicoat, Enid Y. N. Lam, Tatiana Caneque, Marian L. Burr, Veronique Litalien, Giovanna Pomilio, Mathilde Poplineau, Estelle Duprez, Sarah-Jane Dawson, Georg Ramm, Andrew G. Cox, Kristin K. Brown, David C. S. Huang, Andrew H. Wei, Kate McArthur, Raphael Rodriguez, Mark A. Dawson

Summary: Ironomycin is a drug that disrupts mitochondrial metabolism and induces cell death in cancer cells by reducing mitochondrial iron load and activating BAX/BAK. It exhibits synergy with BH3 mimetics and overcomes venetoclax resistance in cancers such as acute myeloid leukemia.

CANCER DISCOVERY (2022)

Add to Collection

Letter Hematology

Ibrutinib use, treatment duration, and concomitant medications in Australian patients with relapsed or refractory chronic lymphocytic leukaemia

Stephen P. Mulligan, Stephen Opat, Paula Marlton, Bryone Kuss, Poppy Gerungan, Andrea Puig, Marija McGeachie, Constantine S. Tam

BRITISH JOURNAL OF HAEMATOLOGY (2022)

Add to Collection

Letter Medicine, General & Internal

Fitness criteria for Australian patients referred for chimeric antigen receptor T-cell therapy

Constantine S. Tam, P. J. Ho, Duncan Purtill, Emily Blyth, Jason Butler, Michael Dickinson, Simon Harrison

INTERNAL MEDICINE JOURNAL (2022)

Add to Collection

Letter Medicine, General & Internal

Recommendation for TP53 mutation testing in newly diagnosed mantle cell lymphoma: a statement from working groups sponsored by the Victorian Comprehensive Cancer Centre

Constantine S. Tam, Gareth P. Gregory, Matthew Ku, Shaun Fleming, Sasanka M. Handunnetti, Denise Lee, Patricia Walker, Andrew Perkins, Thomas E. Lew, Shreerang Sirdesai, Chong Chyn Chua, Michael Gilbertson, Masa Lasica, Mary Ann Anderson, William Renwick, Andrew Grigg, Sush Patil, Stephen Opat, Adam Friebe, Rachel Cooke, Jasper De Boer, Andrew Spencer, David Ritchie, Rishu Agarwal, Piers Blombery

INTERNAL MEDICINE JOURNAL (2022)

Add to Collection

Letter Hematology

Long-term safety for patients with tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma

Ulrich Jaeger, Constantine S. Tam, Peter Borchmann, Joseph P. McGuirk, Marianne Johansen, Edmund K. Waller, Samantha Jaglowski, Charalambos Andreadis, Stephen R. Foley, Jason R. Westin, Isabelle Fleury, P. Joy Ho, Stephan Mielke, Takanori Teshima, Gilles Salles, Stephen J. Schuster, Fiona He, Richard T. Maziarz, Sebastian Mayer, Shinichi Makita, Marie J. Kersten, Monalisa Ghosh, Nina Wagner-Johnston, Koji Kato, Paolo Corradini, Hideki Goto, Silvia Colicino, Abhijit Agarwal, Chiara Lobetti-Bodoni, Michael R. Bishop

BLOOD ADVANCES (2022)

Add to Collection

Article Oncology

Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial

Peter Hillmen, Barbara Eichhorst, Jennifer R. Brown, Nicole Lamanna, Susan M. O'Brien, Constantine S. Tam, Lugui Qiu, Maciej Kazmierczak, Keshu Zhou, Martin Simkovic, Jiri Mayer, Amanda Gillespie-Twardy, Mazyar Shadman, Alessandra Ferrajoli, Peter S. Ganly, Robert Weinkove, Sebastian Grosicki, Andrzej Mital, Tadeusz Robak, Anders Osterborg, Habte A. Yimer, Tommi Salmi, Meng Ji, Jessica Yecies, Adam Idoine, Kenneth Wu, Jane Huang, Wojciech Jurczak

Summary: The study compared the efficacy and safety of zanubrutinib and ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia. The results showed that zanubrutinib had better outcomes in terms of efficacy, atrial fibrillation rate, and cardiac safety compared to ibrutinib.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Add to Collection

Article Cell Biology

Targeting Menin disrupts the KMT2A/B and polycomb balance to paradoxically activate bivalent genes

Christina E. Sparbier, Andrea Gillespie, Juliana Gomez, Nishi Kumari, Ali Motazedian, Kah Lok Chan, Charles C. Bell, Omer Gilan, Yih-Chih Chan, Sarah Popp, Daniel J. Gough, Melanie A. Eckersley-Maslin, Sarah-Jane Dawson, Paul J. Lehner, Kate D. Sutherland, Patricia Ernst, Gerard M. McGeehan, Enid Y. N. Lam, Marian L. Burr, Mark A. Dawson

Summary: By using a cell surface readout of bivalent MHC class I gene expression and whole-genome CRISPR-Cas9 screens, specific roles for MTF2-PRC2.1, PCGF1-PRC1.1, and Menin-KMT2A/B complexes in maintaining bivalency are identified. Menin and KMT2A/B have separate functions in maintaining H3K4me3 and opposing polycomb-mediated repression at bivalent genes. Targeted release of KMT2A by Menin alters the balance of polycomb and KMT2A at bivalent genes, facilitating gene activation.

NATURE CELL BIOLOGY (2023)

Add to Collection

Letter Hematology

Variant acute promyelocytic leukaemia with novel NAB2::RARA fusion shows clinical all-trans retinoic acid and arsenic trioxide sensitivity

Melissa Ng Liet Hing, Georgina L. Ryland, Tamia Nguyen, Ing Soo Tiong, Karen Dun, Slavisa Ninkovic, Rithin Nedumannil, David A. Westerman, Piers A. Blombery, Kah Lok Chan, Ashish Bajel

BRITISH JOURNAL OF HAEMATOLOGY (2023)

Add to Collection

Article Oncology

Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia

John N. Allan, Ian W. Flinn, Tanya Siddiqi, Paolo Ghia, Constantine S. Tam, Thomas J. Kipps, Paul M. Barr, Anna Elinder Camburn, Alessandra Tedeschi, Xavier C. Badoux, Ryan Jacobs, Bryone J. Kuss, Livio Trentin, Cathy Zhou, Anita Szoke, Christopher Abbazio, William G. Wierda

Summary: The CAPTIVATE study demonstrates that fixed-duration ibrutinib plus venetoclax is effective in controlling chronic lymphocytic leukemia, including patients with high-risk genomic features. This treatment provides durable progression-free survival and similar overall survival rates.

CLINICAL CANCER RESEARCH (2023)

Add to Collection

Article Hematology

Report of consensus panel 7 from the 11th international workshop on Waldenstrom macroglobulinemia on priorities for novel clinical trials

C. S. Tam, P. Kapoor, J. J. Castillo, C. Buske, S. M. Ansell, A. R. Branagan, E. Kimby, Y. Li, M. L. Palomba, L. Qiu, M. Shadman, J. P. Abeykoon, S. Sarosiek, J. M. Vos, S. Yi, D. Stephens, D. Roos-Weil, A. M. Roccaro, P. Morel, N. C. Munshi, K. C. Anderson, J. San-Miguel, R. Garcia-Sanz, M. A. Dimopoulos, S. P. Treon, M. J. Kersten

Summary: Recent advances in understanding WM biology have influenced the development of novel agents and improved knowledge of WM genomics. CP7 examined completed and ongoing clinical trials and made recommendations for future trials, prioritizing limited duration and novel agent combinations. Evaluating MYD88, CXCR4, and TP53 at baseline and using bendamustine-rituximab or dexamethasone, rituximab and cyclophosphamide as standard treatments were suggested. Unanswered questions include defining frailty, determining the importance of achieving VGPR within a specific time frame, and providing optimal treatment for WM populations with special needs.

SEMINARS IN HEMATOLOGY (2023)

Add to Collection

Letter Hematology

Real-world experience of combined treatment with azacitidine and romidepsin in patients with peripheral T-cell lymphoma

Matko Kalac, Salvia Jain, Constantine S. Tam, Zhengrui Xiao, Francesca Montanari, Jennifer Kanakry, Bryan D. Huber, Mendel Goldfinger, Owen A. O'Connor, Enrica Marchi

BLOOD ADVANCES (2023)

Add to Collection

Letter Hematology

Zanubrutinib for the treatment of relapsed/refractory hairy cell leukemia

Constantine S. Tam, Judith Trotman, Stephen Opat, Jennifer C. Stern, Heather Allewelt, Kunthel By, William Novotny, Jane Huang, Alessandra Tedeschi

BLOOD ADVANCES (2023)

Add to Collection

Article Hematology

Immune restoration with ibrutinib plus venetoclax in first-line chronic lymphocytic leukemia: the phase 2 CAPTIVATE study

Carol Moreno, Isabelle G. Solman, Constantine S. Tam, Andrew Grigg, Lydia Scarfo, Thomas J. Kipps, Srimathi Srinivasan, Raghuveer Singh Mali, Cathy Zhou, James P. Dean, Edith Szafer-Glusman, Michael Choi

Summary: This study evaluated immune cell subsets in patients with CLL who received different treatments. The results demonstrated successful elimination of CLL cells and restoration of normal immune cells in some patients.

BLOOD ADVANCES (2023)

Add to Collection

Article Oncology

Allogeneic stem cell transplantation achieves long-term remissions in mantle cell lymphoma, including in TP53-mutated disease

Thomas E. Lew, Edward R. Scheffer Cliff, Michael Dickinson, Constantine S. Tam, John F. Seymour, Piers Blombery, Ashish Bajel, David Ritchie, Amit Khot

Summary: Cytarabine-containing chemoimmunotherapy followed by autologous transplantation and rituximab maintenance achieves durable remissions for most patients with mantle cell lymphoma (MCL). However, patients with TP53-mutated disease have poor outcomes with standard approaches. Allogeneic stem cell transplantation (alloSCT) can be curative in MCL, including patients with TP53-mutated disease, and should be considered as an earlier treatment option for this subgroup.

LEUKEMIA & LYMPHOMA (2023)

Add to Collection

Review Oncology

Zanubrutinib: past, present, and future

Constantine S. Tam, Javier L. Munoz, John F. Seymour, Stephen Opat

Summary: This article reviews the development of zanubrutinib, a next-generation BTK inhibitor, and its clinical applications in the treatment of B-cell malignancies. Zanubrutinib has shown greater specificity and improved pharmacokinetic properties compared to the first-generation inhibitor, ibrutinib, resulting in improved activity and safety outcomes. The clinical program of zanubrutinib has expanded significantly, with ongoing studies in various hematological malignancies and in combination with other therapies.

BLOOD CANCER JOURNAL (2023)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.